TrialAnnals of surgical oncology2026

A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.

Hironobu Suto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.